IRLAB: Positive end-of-phase II meeting a derisk for Mesdopetam - Redeye

Redeye gives an additional comment on the written minutes from the FDA following the end of phase II-meeting regarding Mesdopetam. We argue that the outcome derisks the regulatory path for Mesdopetam.

Länk till analysen i sin helhet: https://www.redeye.se/research/992551/irlab-positive-end-of-phase-ii-meeting-a-derisk-for-mesdopetam?utm_source=finwire&utm_medium=RSS